Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $365.79

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given an average recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $365.7857.

Several analysts have issued reports on the company. Morgan Stanley upped their price objective on BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th. Jefferies Financial Group restated a “buy” rating and set a $420.00 price objective on shares of BeOne Medicines in a research note on Monday, November 17th. Barclays initiated coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 price objective for the company. Finally, Truist Financial set a $400.00 target price on shares of BeOne Medicines in a report on Monday, November 24th.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,627 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Chan Henry Lee sold 10,671 shares of the stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $350.40, for a total value of $3,739,118.40. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 138,617 shares of company stock worth $44,632,898. Insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently modified their holdings of the company. Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $28,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $35,000. Farther Finance Advisors LLC acquired a new position in shares of BeOne Medicines during the second quarter worth approximately $39,000. Finally, Signaturefd LLC acquired a new position in shares of BeOne Medicines during the second quarter worth approximately $49,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $311.02 on Tuesday. The firm has a market cap of $36.87 billion, a PE ratio of 609.84 and a beta of 0.47. BeOne Medicines has a 1 year low of $172.67 and a 1 year high of $385.22. The firm’s 50-day simple moving average is $326.62 and its 200-day simple moving average is $311.07. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.